Recent Publications
October 2013 Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the diseaseBjörkhem I, Lövgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, Winge K, Pålhagen S, Svenningsson P. Neurosci Lett. 2013 25;555:102-5
23 October 2013 Elevated CNS inflammation in patients with preclinical Alzheimer’s disease Nancy L Monson, Sara J Ireland, Ann J Ligocki, Ding Chen, William H Rounds, + et al.Journal of Cerebral Blood Flow & Metabolism i:10.1038/jcbfm.2013.183
22 October 2013 Dementia: Disclosure of results to participants in dementia research Serge Gauthier & Pedro Rosa-NetoNature Reviews Neurology 9, 608-609 doi:10.1038/nrneurol.2013.213
22 October 2013 Alzheimer disease and stroke: Cognitive and neuroimaging predictors of AD and stroke Clive Ballard & Michael J. O'SullivanNature Reviews Neurology 9, 605-606 doi:10.1038/nrneurol.2013.215
8 October 2013 Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations J Cummings & K ZhongClinical Pharmacology & Therapeutics doi:10.1038/clpt.2013.205
20 August 2013 CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders N Mattsson, P Insel, R Nosheny, H Zetterberg, J Q Trojanowski,+ et al.Translational Psychiatry 3, e293 doi:10.1038/tp.2013.69
13 August 2013 Omics technologies and the study of human ageing Ana M. Valdes, Daniel Glass & Tim D. Spector Nature Reviews Genetics 14, 601-607 doi:10.1038/nrg3604
31 July 2013 Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies David J. Irwin, Virginia M.-Y. Lee & John Q. Trojanowski Nature Reviews Neuroscience 14, 626-636 doi:10.1038/nrn3549
23 July 2013 Dementia: Mild cognitive impairment—amyloid and beyond Philip Scheltens Nature Reviews Neurology 9, 493-495 doi:10.1038/nrneurol.2013.147
16 July 2013 Neurodegenerative disease: Can synucleinopathy and tauopathy be identified during life? Shin-ichiro Kubo & Nobutaka Hattori Nature Reviews Neurology 9, 426-427 doi:10.1038/nrneurol.2013.137
9 July 2013 Alzheimer disease: CSF levels of mitochondrial DNA—a new biomarker for preclinical Alzheimer disease? Katie Kingwell Nature Reviews Neurology 9, 420-420 doi:10.1038/nrneurol.2013.134
25 June 2013 Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease Kaj Blennow, Harald Hampel & Henrik Zetterberg Neuropsychopharmacology doi:10.1038/npp.2013.154
2 October 2013 Modeling Alzheimer’s Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI I Delor, J-E Charoin, R Gieschke, S Retout & P Jacqmin CPT: Pharmacometrics & Systems Pharmacology 2, e78 doi:10.1038/psp.2013.54
7 August 2013 Blood–brain barrier dysfunction as a cause and consequence of Alzheimer’s disease Michelle A Erickson & William A Banks Journal of Cerebral Blood Flow & Metabolism 33, 1500-1513 doi:10.1038/jcbfm.2013.135
6 August 2013 Metabolic profiling of Alzheimer's disease brains Koichi Inoue, Haruhito Tsutsui, Hiroyasu Akatsu, Yoshio Hashizume, Noriyuki Matsukawa, + et al. Scientific Reports 3, doi:10.1038/srep02364
19 February 2013 Cerebrospinal fluid biomarkers in Parkinson disease Lucilla Parnetti, Anna Castrioto, Davide Chiasserini, Emanuele Persichetti, Nicola Tambasco,+ et al.Nature Reviews Neurology 9, 131-140 doi:10.1038/nrneurol.2013.10
10 May 2011 Parkinson disease: PD biomarkers—use of α-synuclein reaches new levels Thomas J. Montine Nature Reviews Neurology 7, 308-309 10.1038/nrneurol.2011.66
29 April 2011 Priorities in Parkinson's disease research Wassilios G. Meissner, Mark Frasier, Thomas Gasser, Christopher G. Goetz, Andres Lozano,+ et al. Nature Reviews Drug Discovery 10, 377-393 doi:10.1038/nrd3430
26 February 2013 Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD Xiaozhen Li, Tie-Qiang Li, Niels Andreasen, Maria Kristoffersen Wiberg, Eric Westman&+ et al. Scientific Reports 3, doi:10.1038/srep01339
11 December 2012 Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease Tiziana Alberio, Agnese C. Pippione, Maurizio Zibetti, Simone Olgiati, Daniela Cecconi, + et al. Scientific Reports 2, doi:10.1038/srep00953
29 August 2013 A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease Penelope G. Foulds, Peter Diggle, J. Douglas Mitchell, Angela Parker, Masato Hasegawa,+ et al.Scientific Reports 3,doi:10.1038/srep02540
June 2007 Can MRI and CSF neurofilament profiles differentiate AD and frontotemporal dementia? Nature Clinical Practice Neurology 3, 300-301 doi:10.1038/ncpneuro0478
11 June 2013 Ushering in the study and treatment of preclinical Alzheimer disease Jessica B. Langbaum, Adam S. Fleisher, Kewei Chen, Napatkamon Ayutyanont, Francisco Lopera, + et al.Nature Reviews Neurology 9, 371-381doi:10.1038/nrneurol.2013.107